We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin. The most probable cause of his CMV colitis is the impaired immunity during a phase of neutropenia after the chemotherapy. Although there was amelioration of the colitis and clinical status after treatment with ganciclovir, the patient later deteriorated and died due to recurrent bacterial infections. This is the third reported case of CMV colitis treated with ganciclovir in a patient with a solid tumour. It is the first report of CMV colitis after docetaxel containing chemotherapy.
Summary
We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin. The most probable cause of his CMV colitis is the impaired immunity during a phase of neutropenia after the chemotherapy. Although there was amelioration of the colitis and clinical status after treatment with ganciclovir, the patient later deteriorated and died due to recurrent bacterial infections. This is the third reported case of CMV colitis treated with ganciclovir in a patient with a solid tumour. It is the first report of CMV colitis after docetaxel containing chemotherapy.
Although CMV colitis is most frequently observed in immunosuppressed patients such as those with acquired immune deficiency syndrome (AIDS), transplants and corticosteroid treatment, it has also been reported in less immunosuppressed (elderly, malnourished, ...) and even non-immunosuppressed patients. CMV infection should therefore be included in the differential diagnosis of GI disease in all patients, and when suspected, the clinician should pursue appropriate diagnostic and therapeutic interventions.
Key words: cancer, chemotherapy, colitis, cytomegalovirus, docetaxel, hypopharynx Case A 53-year-old male with alcohol and nicotine abuse was diagnosed with a T j^b M o , stage IV, well differentiated spinocellular carcinoma of the hypopharynx. Neoadjuvant chemotherapy was started: the combination of docetaxel (75 mg/m 2 , day 1), 5-fluorouracil (5-FU, 750 mg/m 2 , day 1-5) and cisplatin (75 mg/m 2 , day 1) was used, in a phase I-II study. He received a total of six times 32 mg of methylprednisolone orally (on day -1, 0 and 1) and once 8 mg of dexamethasone intravenously (on day 0) as pre-and postmedication.
On day 8 he became anorectic, neutropenic (320 x 10 6 /l neutrophils) and developed a severe diarrhoea, about hourly, which was occasionally bloody. Bacterial stoolcultures showed a normal gut flora. No parasites and no clostridium difficile toxin were found. Loperamide was started and the patient was hospitalized for enteral feeding.
Five days later he had a temperature of 38 °C with persistent diarrhoea; the white blood cell (WBC) count was 11 400 x 1O 6 /1. Amoxicillin/clavulanic acid was started intravenously. All bacterial cultures remained negative or normal. Microscopic examination of the faeces showed > 100 WBC/field, without red blood cells. Clinically the colon was distended and pressuresensitive. Radiographs of the abdomen with barium contrast showed a moderately dilated small bowel with slowed motility; there was a severely dilated colon, in particular the transverse colon, with loss of haustration, deep mucosal ulcerations and inflammatory pseudopolyps.
An ileocolonoscopy showed a normal ileum but severe ulcerative pancolitis with deep ulcerations, pseudopolyps and some pseudomembranes. Biopsies showed chronic inflammation, granulation tissue and several large cells with cytomegalovirus (CMV) inclusions. Immunohistochemistry with CMV antibodies (Klinipath AM 254-5M) showed immunoreactivity in the nucleus and sometimes in the cytoplasm of these cells (Figure 1 ). The diagnosis of CMV colitis was made, four weeks after the start of the diarrhoea. The antibiotics were stopped. Ganciclovir was started (5 mg/kg/12 hours i.v. for three weeks). No further chemotherapy was administered. Consolidation radiotherapy of the hypopharynx and draining lymph nodes was started. Dexamethasone 8 mg daily was given because of stridor.
CMV serology (five weeks after the start of the diarrhoea) showed a borderline elevated IgM titer and a total antibody titer of > 3200. Two weeks later the IgM serology was negative. One and two months later the IgM titer remained negative and the total antibody titer dropped to 1600 and 800, respectively. Human immunodeficiency virus (HIV) serology was negative.
After three weeks the fever had disappeared and ganciclovir was stopped. Another two weeks later a second colonoscopy was performed which showed persistent but diminished ulcerative pancolitis with pseudo- polyps and pseudomembranes. Biopsies showed chronic colitis and ulcerations but CMV immunoreactive cells were no longer present. His fever had disappeared. Diarrhoea had resolved, peristalsis had normalised and the dilatation of the colon had diminished.
In the months following, the patient developed recurrent gram-negative pneumonias and a disseminated Candida albicans infection. He died more than four months after his hospitalisation as a result of a gram-negative pneumonia.
The autopsy showed bilateral pneumonia, pyelonephritis, a residual tumour mass in the hypopharynx and persisting colonic ulcerations without CMV immunoreactive cells.
Discussion
Cytomegalovirus is an infectious agent that usually causes low morbidity [1] ; its prevalence is high, especially in the homosexual community [2] . In the US, CMV can be isolated in 81% of the population over 35 years of age [3] . These individuals have elevated CMV titers but clinical evidence of disease is relatively rare. Primary CMV infection in immunocompetent individuals usually is asymptomatic or results in a mononucleosis-like syndrome with fever, myalgias, sore throat, rash, adenopathy and/or acute hepatitis [4] . Serious infections are mostly pulmonary or hepatic, but also ophthalmic, or involving the central nervous system or gastrointestinal (GI) tract [1] . They are generally limited to severely immunodepressed patients as solid organ or bone marrow transplant recipients or AIDS patients [4] , but are also seen in patients with haematological or other malignancies, inflammatory bowel disease or during immunosuppressant therapy.
Involvement of the GI tract is usually associated with disseminated CMV disease in patients immunosuppressed due to HIV infection or immunosuppressive medication and/or in patients with organ or bone marrow transplantation (BMT). It has also been documented in those with malignant disease, in patients receiving therapy with corticosteroids or cytotoxic drugs, or in patients with chronic inflammatory bowel disease [5, 6] . GI tract involvement is the second most common clinical manifestation of CMV in patients with the acquired immune deficiency syndrome (AIDS). In one study 67% of these infections were found in the colon, the most common site of infection [7] .
In immunocompromised patients, GI involvement is serious and often associated with diarrhoea, abdominal pain, hemorrhage, and even perforation [8] . Pneumatosis intestinalis, myenteric plexus involvement with intestinal pseudo-obstruction and hemorrhoiditis [9] are infrequently noted. The symptoms of GI CMV disease typically result from ulceration of the GI mucosa.
CMV disease of the GI tract specifically was already well described before the era of transplantations and AIDS. As in the other disease manifestations, virtually all the patients described were immunocompromised. The underlying conditions reported most frequently were malignancies, collagen vascular diseases (particularly in patients treated with cytotoxic agents or corticosteroids), and other conditions in which corticosteroids or immunosuppressive agents were used, such as chronic obstructive pulmonary disease, interstitial nephritis, immune thrombocytopenia and hemolytic anemia [10] . There have been sporadic cases of CMV colitis in not severely or nonimmunocompromised persons.
The diagnosis of CMV disease requires the demonstration of infection plus gross pathological abnormalities. The best diagnostic test for invasive CMV disease is a biopsy, which characteristically shows cytomegalic cells with large nuclei containing large, central, basophilic intranuclear inclusions [11] . The sensitivity of the histology of GI mucosal biopsies can be increased by obtaining deep biopsy specimens that include endothelial cells and fibroblasts in the lamina propria because these cells are more likely than epithelial cells to be infected by CMV [11] . Abnormal cytopathology correlates more with significant disease than does isolation of virus in culture [11] . CMV infection of the GI tract, which is not the same as CMV disease, can be demonstrated by culture of CMV from GI tissue, detection of CMV antigen in tissue, detection of CMV virions by electron microscopy, detection of CMV genome in tissue, or detection of typical CMV cytopathology [11] . However, tests for the presence of GI CMV infection such as stool cultures or swabs of the mucosa indicate viral shedding and do not necessarily prove that tissue-invasive CMV disease is present. CMV inclusion bodies are not seen in all cases of CMV disease. Some authors therefore recommend that cultures be performed by adding the processed tissue specimens to human fibroblasts and examining for cytopathic effects over the course of 10-14 days [12] . The shell-vial culture technique allows for specific diagnosis at 18-36 hours [12] . Polymerase chain reaction (PCR) techniques cannot differentiate between CMV infection and CMV disease but can be used for early detection of CMV [12] .
Endoscopic findings of CMV disease include erythema, erosions and ulcerations [13] . Less commonly plaques, nodules and polyps are seen.
The radiological findings in CMV disease are nonspecific but can, combined with the clinical information, be highly suggestive of GI CMV disease [14] . Typical findings from upper GI studies of 16 proven cases of GI CMV disease in patients with AIDS were segmental or focal involvement, mucosal granularity, erosions, ulcerations and irregular thickening of mucosal folds, isolated deep ulcerations and ulcers projecting intraluminally [15] . Barium enema examinations in patients with CMV colitis showed severe mucosal irregularity and ulcerations, luminal narrowing, thumb printing, and even tumour-like defects due to severe local swelling; the caecum was the most frequently affected site [14] .
Since invasive procedures are required to establish the diagnosis of GI CMV disease, GI involvement is often not diagnosed as quickly as CMV pneumonitis or hepatitis, for which radiographic examination and blood tests lend strong clinical evidence. The diagnosis of GI CMV disease may be delayed by days or weeks.
Historically, complications of CMV disease of the GI tract have been fatal in as many as 83% of affected patients [16] , The use of ganciclovir or foscarnet, however, has dramatically improved the prognosis. There were no deaths in a study of bone marrow transplant recipients with CMV disease of the GI tract where all the patients were treated with ganciclovir [17] . Ganciclovir has also proved to be effective in AIDS patients with GI CMV disease [18] . This is the third reported case of CMV colitis treated with ganciclovir in a patient with a solid tumour and the first report of CMV colitis after docetaxel containing chemotherapy [19, 20] . In both previously described cases of CMV colitis, colitis developed after chemotherapy for small-cell lung cancer (one patient) and pancreatic carcinoma (one patient). Both times ganciclovir 5 mg/kg b.i.d. was given intravenously for 14 days. The diarrhoea resolved after four and eight days, respectively. In our case ganciclovir was given for three weeks and the diarrhoea only stopped after two weeks, with just partial resolution of the colonic dilatation.
The dosages of ganciclovir used in the treatment of GI CMV disease range from 2.5 to 5.0 mg/kg i.v. every 12 hours, for at least 2 weeks. The dose must be adjusted for renal function. Although generally well tolerated, bone marrow suppression has limited the dosage or duration of therapy in some patients. In most cases the toxicity was reversible with a reduction in the dose or with discontinuation of the drug. Although relapses after ganciclovir therapy for CMV disease of the GI tract occur in up to 40% of immunocompromised patients without AIDS, there is little evidence to recommend routine use of maintenance therapy. Maintenance therapy with ganciclovir can be considered for the unusual patient with frequently recurring episodes of GI CMV disease if there is no evidence of viral resistance and if adverse effects are manageable.
Therapy with other agents as acyclovir, vidarabine and interferon have not reduced mortality or provided consistent antiviral activity. Foscarnet, a newer antiviral drug, possesses good activity against CMV and has been used successfully in treatment of GI CMV infections in patients with AIDS [21] . No studies have reported the efficacy of foscarnet in GI CMV disease in patients without AIDS. Whenever possible immunosuppressive therapy has to be reduced when treating CMV disease.
5-FU is associated with diarrhoea and inflammation along the GI tract that most often occurs when it is given as a continous infusion [22] , as was the case here. Mild diarrhoea has also been described after docetaxel infusion [23] . Mitotic arrest with epithelial necrosis and ulceration in the esophagus after treatment with paclitaxel, another taxane, has also been described, with mitotic arrests also found in stomach, small intestine, colon, liver and bone marrow [24] . It is possible that inflammation of the colon, caused by the chemotherapy, facilitated the appearance of a CMV colitis. However, the immunosuppressed (neutropenic) state after the chemotherapy probably played a more important role since cell-mediated immunity is important in the defence against CMV. This is the third reported case of CMV colitis treated with ganciclovir in a patient with a solid tumour [19, 20] and the first report after docetaxel containing chemotherapy. Although CMV colitis is most frequently observed in immunosuppressed patients such as those with AIDS, transplant and corticosteroid treatment, it has also been reported in less immunosuppressed (elderly, malnourished, ...) and even non-immunosuppressed patients [5, 6] . CMV infection should therefore be included in the differential diagnosis of GI disease in all patients with severe diarrhoea, and when suspected, the clinician should pursue appropriate diagnostic and therapeutic interventions.
